Carbios SAS Valuation

Is ALCRB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALCRB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALCRB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALCRB's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALCRB?

Key metric: As ALCRB barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ALCRB. This is calculated by dividing ALCRB's market cap by their current book value.
What is ALCRB's PB Ratio?
PB Ratio0.6x
Book€217.55m
Market Cap€132.43m

Price to Book Ratio vs Peers

How does ALCRB's PB Ratio compare to its peers?

The above table shows the PB ratio for ALCRB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.7x
EXPL EPC Groupe
2.6x25.1%€396.5m
ALAFY AFYREN SAS
1.1x14.4%€60.5m
ALGBE Global Bioenergies
3.1x-4.0%€14.1m
PVL Plastiques du Val de Loire
0.1x85.4%€26.9m
ALCRB Carbios SAS
0.6x3.3%€132.4m

Price-To-Book vs Peers: ALCRB is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (1.7x).


Price to Book Ratio vs Industry

How does ALCRB's PB Ratio compare vs other companies in the FR Chemicals Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
PVL Plastiques du Val de Loire
0.1x85.4%US$28.29m
METEX METabolic EXplorer
0.06xn/aUS$6.75m
No more companies available in this PB range
ALCRB 0.6xIndustry Avg. 1.4xNo. of Companies4PB00.81.62.43.24+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ALCRB is good value based on its Price-To-Book Ratio (0.6x) compared to the European Chemicals industry average (1.4x).


Price to Book Ratio vs Fair Ratio

What is ALCRB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALCRB PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALCRB's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALCRB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€7.40
€57.67
+679.3%
22.0%€75.00€45.00n/a3
Nov ’25€10.34
€57.67
+457.7%
22.0%€75.00€45.00n/a3
Oct ’25€16.78
€61.00
+263.5%
16.3%€75.00€53.00n/a3
Sep ’25€20.80
€58.50
+181.2%
16.5%€75.00€51.00n/a4
Aug ’25€20.55
€58.50
+184.7%
16.5%€75.00€51.00n/a4
Jul ’25€21.50
€58.50
+172.1%
16.5%€75.00€51.00n/a4
Jun ’25€25.75
€58.50
+127.2%
16.5%€75.00€51.00n/a4
May ’25€22.85
€58.50
+156.0%
16.5%€75.00€51.00n/a4
Apr ’25€24.10
€59.00
+144.8%
15.9%€75.00€51.00n/a4
Mar ’25€25.70
€59.00
+129.6%
15.9%€75.00€51.00n/a4
Feb ’25€22.10
€59.00
+167.0%
15.9%€75.00€51.00n/a4
Jan ’25€28.05
€59.00
+110.3%
15.9%€75.00€51.00n/a4
Dec ’24€22.05
€59.00
+167.6%
15.9%€75.00€51.00n/a4
Nov ’24€20.30
€60.10
+196.1%
15.1%€75.00€51.00€10.344
Oct ’24€22.00
€60.10
+173.2%
15.1%€75.00€51.00€16.784
Sep ’24€24.80
€63.13
+154.6%
13.6%€75.00€55.00€20.803
Aug ’24€26.30
€59.00
+124.3%
20.0%€75.00€47.00€20.553
Jul ’24€35.00
€62.00
+77.1%
18.6%€75.00€47.00€21.503
Jun ’24€34.65
€54.00
+55.8%
21.0%€70.00€45.00€25.753
May ’24€31.55
€54.00
+71.2%
21.0%€70.00€45.00€22.853
Apr ’24€35.78
€54.00
+50.9%
21.0%€70.00€45.00€24.103
Mar ’24€39.20
€54.00
+37.8%
21.0%€70.00€45.00€25.703
Feb ’24€37.02
€54.00
+45.9%
21.0%€70.00€45.00€22.103
Jan ’24€34.22
€54.00
+57.8%
21.0%€70.00€45.00€28.053
Dec ’23€33.98
€54.00
+58.9%
21.0%€70.00€45.00€22.053
Nov ’23€32.86
€54.00
+64.3%
21.0%€70.00€45.00€20.303

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies